Impact of Sleeve Gastrectomy on Kidney Function and Preemptive Transplant in Kidney Transplant Candidates With Obesity

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10499119" target="_blank" >RIV/00179906:_____/25:10499119 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/25:10499119

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=U9--XQHNJ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=U9--XQHNJ</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.mayocp.2024.10.024" target="_blank" >10.1016/j.mayocp.2024.10.024</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Impact of Sleeve Gastrectomy on Kidney Function and Preemptive Transplant in Kidney Transplant Candidates With Obesity

Popis výsledku v původním jazyce

Objective: To compare the impact of sleeve gastrectomy (SG) on kidney function, comorbidities, and kidney transplant (KT) rates in KT candidates with obesity with a nonsurgical cohort. Methods: Twenty-one KT candidates with body mass index (BMI) above 35 kg/m2 underwent SG between February 26, 2021, and October 27, 2023, and were compared with 19 who did not have SG. The secondary endpoints included changes in BMI, requirements for antihyperglycemic and anti-hypertension medications, and preemptive KT rates. Results: The mean estimated glomerular filtration rate (eGFR) increased from a pre-SG baseline of 16.7 +/- 5.4 to 23.5 +/- 8.3 and 23.5 +/- 8.6 mL/min per 1.73 m2 at 2 and 6 months after SG (P=.002 and .02, respectively), whereas it remained unchanged in the non-SG cohort: 13.8 +/- 3.4, 14.3 +/- 5.1, and 14.8 +/- 6.4 mL/min per 1.73 m2 at the pre-evaluation period, 2 months, and 6 months. A higher baseline eGFR correlated with an improvement in eGFR after SG. The BMI and insulin requirements decreased only in the SG cohort. During the follow-up period of 5.1 +/- 4.6 months, 5 (23.8%) patients in the SG cohort and no patient in the non-SG cohort underwent preemptive KT. Conclusion: Pretransplant SG improves kidney function and may consequently increase rates of preemptive KT in candidates not yet on dialysis. These findings need to be confirmed by prospective studies with a well-matched cohort. 2024 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Název v anglickém jazyce

Impact of Sleeve Gastrectomy on Kidney Function and Preemptive Transplant in Kidney Transplant Candidates With Obesity

Popis výsledku anglicky

Objective: To compare the impact of sleeve gastrectomy (SG) on kidney function, comorbidities, and kidney transplant (KT) rates in KT candidates with obesity with a nonsurgical cohort. Methods: Twenty-one KT candidates with body mass index (BMI) above 35 kg/m2 underwent SG between February 26, 2021, and October 27, 2023, and were compared with 19 who did not have SG. The secondary endpoints included changes in BMI, requirements for antihyperglycemic and anti-hypertension medications, and preemptive KT rates. Results: The mean estimated glomerular filtration rate (eGFR) increased from a pre-SG baseline of 16.7 +/- 5.4 to 23.5 +/- 8.3 and 23.5 +/- 8.6 mL/min per 1.73 m2 at 2 and 6 months after SG (P=.002 and .02, respectively), whereas it remained unchanged in the non-SG cohort: 13.8 +/- 3.4, 14.3 +/- 5.1, and 14.8 +/- 6.4 mL/min per 1.73 m2 at the pre-evaluation period, 2 months, and 6 months. A higher baseline eGFR correlated with an improvement in eGFR after SG. The BMI and insulin requirements decreased only in the SG cohort. During the follow-up period of 5.1 +/- 4.6 months, 5 (23.8%) patients in the SG cohort and no patient in the non-SG cohort underwent preemptive KT. Conclusion: Pretransplant SG improves kidney function and may consequently increase rates of preemptive KT in candidates not yet on dialysis. These findings need to be confirmed by prospective studies with a well-matched cohort. 2024 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Mayo Clinic Proceedings

ISSN

0025-6196

e-ISSN

1942-5546

Svazek periodika

100

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

942-953

Kód UT WoS článku

001516270500001

EID výsledku v databázi Scopus

2-s2.0-105003883631